These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

78 related articles for article (PubMed ID: 22820082)

  • 1. Myeloperoxidase and free iron levels: potential biomarkers for early detection and prognosis of ovarian cancer.
    Fletcher NM; Jiang Z; Ali-Fehmi R; Levin NK; Belotte J; Tainsky MA; Diamond MP; Abu-Soud HM; Saed GM
    Cancer Biomark; 2011-2012; 10(6):267-75. PubMed ID: 22820082
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum sErbB1 and epidermal growth factor levels as tumor biomarkers in women with stage III or IV epithelial ovarian cancer.
    Baron AT; Lafky JM; Boardman CH; Balasubramaniam S; Suman VJ; Podratz KC; Maihle NJ
    Cancer Epidemiol Biomarkers Prev; 1999 Feb; 8(2):129-37. PubMed ID: 10067810
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum profiling to distinguish early- and late-stage ovarian cancer patients from disease-free individuals.
    Hocker JR; Bishop EA; Lightfoot SA; Lerner MR; Peyton MD; Brackett DJ; Hanas RJ; McMeekin DS; Walker JL; Hanas JS
    Cancer Invest; 2012 Feb; 30(2):189-97. PubMed ID: 22149058
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Study on serum vascular endothelial growth factor level in ovarian malignant tumors].
    Li L; Wang LM; Zhang W; Zhang JQ; Song HL; Yao DS; Tang Y; Chen XQ; Yang ZH
    Zhonghua Fu Chan Ke Za Zhi; 2003 Feb; 38(2):72-6. PubMed ID: 12783691
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Identification of two potential serum biomarkers for ovarian cancer and clinical validation thereof].
    Wang Q; Zhang W; Li DR; Li L
    Zhonghua Yi Xue Za Zhi; 2008 Apr; 88(15):1012-6. PubMed ID: 18754431
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of biomarker panels for early stage ovarian cancer detection and monitoring for disease recurrence.
    Havrilesky LJ; Whitehead CM; Rubatt JM; Cheek RL; Groelke J; He Q; Malinowski DP; Fischer TJ; Berchuck A
    Gynecol Oncol; 2008 Sep; 110(3):374-82. PubMed ID: 18584856
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Validation of serum biomarkers for detection of early-stage ovarian cancer.
    Nosov V; Su F; Amneus M; Birrer M; Robins T; Kotlerman J; Reddy S; Farias-Eisner R
    Am J Obstet Gynecol; 2009 Jun; 200(6):639.e1-5. PubMed ID: 19285648
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multianalyte profiling of serum antigens and autoimmune and infectious disease molecules to identify biomarkers dysregulated in epithelial ovarian cancer.
    Bertenshaw GP; Yip P; Seshaiah P; Zhao J; Chen TH; Wiggins WS; Mapes JP; Mansfield BC
    Cancer Epidemiol Biomarkers Prev; 2008 Oct; 17(10):2872-81. PubMed ID: 18843033
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Soluble epidermal growth factor receptor (sEGFR) [corrected] and cancer antigen 125 (CA125) as screening and diagnostic tests for epithelial ovarian cancer.
    Baron AT; Boardman CH; Lafky JM; Rademaker A; Liu D; Fishman DA; Podratz KC; Maihle NJ
    Cancer Epidemiol Biomarkers Prev; 2005 Feb; 14(2):306-18. PubMed ID: 15734951
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The serum concentration of human kallikrein 10 represents a novel biomarker for ovarian cancer diagnosis and prognosis.
    Luo LY; Katsaros D; Scorilas A; Fracchioli S; Bellino R; van Gramberen M; de Bruijn H; Henrik A; Stenman UH; Massobrio M; van der Zee AG; Vergote I; Diamandis EP
    Cancer Res; 2003 Feb; 63(4):807-11. PubMed ID: 12591730
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serum evaluation of interleukin 6 in ovarian cancer patients.
    Tempfer C; Zeisler H; Sliutz G; Haeusler G; Hanzal E; Kainz C
    Gynecol Oncol; 1997 Jul; 66(1):27-30. PubMed ID: 9234916
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Afamin and apolipoprotein A-IV: novel protein markers for ovarian cancer.
    Dieplinger H; Ankerst DP; Burges A; Lenhard M; Lingenhel A; Fineder L; Buchner H; Stieber P
    Cancer Epidemiol Biomarkers Prev; 2009 Apr; 18(4):1127-33. PubMed ID: 19336561
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Detection of serum transforming growth factor-alpha in patients of primary epithelial ovarian cancers by enzyme immunoassay.
    Chien CH; Huang CC; Lin YH; Shen J; Chow SN
    Gynecol Oncol; 1997 Sep; 66(3):405-10. PubMed ID: 9299253
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diagnostic and prognostic values of plasma levels of fibrinolytic markers in ovarian cancer.
    Ho CH; Yuan CC; Liu SM
    Gynecol Oncol; 1999 Dec; 75(3):397-400. PubMed ID: 10600296
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [The values of serum human epididymis secretory protein 4 and CA(125) assay in the diagnosis of ovarian malignancy].
    Dong L; Chang XH; Ye X; Zhu LR; Zhao Y; Tian L; Cheng HY; Li XP; Zhang H; Liao QP; Fu TY; Cheng YX; Cui H
    Zhonghua Fu Chan Ke Za Zhi; 2008 Dec; 43(12):931-6. PubMed ID: 19134334
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Value of serum CA(125) detection for predicting recurrence and prognosis in ovarian epithelial cancer].
    Wang XY; Ye J; Feng SW; Lü WG; Wan XY; Xie X
    Zhonghua Fu Chan Ke Za Zhi; 2010 Nov; 45(11):813-6. PubMed ID: 21211277
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Shed membrane fragment-associated markers for endometrial and ovarian cancers.
    Taylor DD; Lyons KS; Gerçel-Taylor C
    Gynecol Oncol; 2002 Mar; 84(3):443-8. PubMed ID: 11855885
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Relapse and survival in early-stage ovarian cancer.
    Lenhard SM; Bufe A; Kümper C; Stieber P; Mayr D; Hertlein L; Kirschenhofer A; Friese K; Burges A
    Arch Gynecol Obstet; 2009 Jul; 280(1):71-7. PubMed ID: 19093129
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serum paraoxonase and arylesterase activities in patients with epithelial ovarian cancer.
    Camuzcuoglu H; Arioz DT; Toy H; Kurt S; Celik H; Erel O
    Gynecol Oncol; 2009 Mar; 112(3):481-5. PubMed ID: 19101714
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preoperative serum tetranectin, CA125 and menopausal status used as single markers in screening and in a risk assessment index (RAI) in discriminating between benign and malignant ovarian tumors.
    Begum FD; Høgdall E; Kjaer SK; Blaakaer J; Christensen IJ; Christensen L; Høgdall C
    Gynecol Oncol; 2009 May; 113(2):221-7. PubMed ID: 19261323
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.